Copyright
©The Author(s) 2018.
World J Clin Cases. May 16, 2018; 6(5): 74-83
Published online May 16, 2018. doi: 10.12998/wjcc.v6.i5.74
Published online May 16, 2018. doi: 10.12998/wjcc.v6.i5.74
Table 4 Comparison of overall survival in patients with hepatocellular carcinoma treated with sorafenib and those treated with sorafenib plus transarterial chemoembolization
Annual survival rate (%) | mOS (mo) | P value | |||
1 yr | 2 yr | 3 yr | |||
Sorafenib + TACE | 94.7 | 63.2 | 34.6 | 35.2 | < 0.001 |
TACE | 96.6 | 42 | NA | 22 |
- Citation: Lei XF, Ke Y, Bao TH, Tang HR, Wu XS, Shi ZT, Lin J, Zhang ZX, Gu H, Wang L. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study. World J Clin Cases 2018; 6(5): 74-83
- URL: https://www.wjgnet.com/2307-8960/full/v6/i5/74.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v6.i5.74